A DPC Database Study on the Safety of Atezolizumab/Bevacizumab/Carboplatin/Paclitaxel in Non-small Cell Lung Cancer in Japanese Patients
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
A DPC Database Study on the Safety of Atezolizumab/Bevacizumab/Carboplatin/Paclitaxel in Non-small Cell Lung Cancer in Japanese Patients ; volume:41 ; number:9 ; day:11 ; month:7 ; year:2024 ; pages:3520-3538 ; date:9.2024
Advances in therapy ; 41, Heft 9 (11.7.2024), 3520-3538, 9.2024
- Creator
-
Hata, Akito
Iwasawa, Shunichiro
Sasaki, Yusuke
Tajima, Kosei
Chiba, Yasutaka
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s12325-024-02921-x
- URN
-
urn:nbn:de:101:1-2411130727086.999264807798
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:23 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Hata, Akito
- Iwasawa, Shunichiro
- Sasaki, Yusuke
- Tajima, Kosei
- Chiba, Yasutaka
- SpringerLink (Online service)
Other Objects (12)
Atezolizumab (NSCLC; Kombination mit Bevacizumab, Carboplatin und Paclitaxel) : Nutzenbewertung gemäß § 35a SGB V
Atezolizumab (NSCLC, Kombination mit nab-Paclitaxel und Carboplatin) : Nutzenbewertung gemäß § 35a SGB V
Atezolizumab (NSCLC, Kombination mit nab-Paclitaxel und Carboplatin) : Nutzenbewertung gemäß § 35a SGB V
Phase II study of carboplatin/nab-paclitaxel/atezolizumab combination therapy for advanced nonsquamous non–small cell lung cancer patients with impaired renal function: RESTART trial
[18F]FDG PET/CT-based response assessment of stage IV non-small cell lung cancer treated with paclitaxel-carboplatin-bevacizumab with or without nitroglycerin patches
Complete Response of Recurrent Small Cell Carcinoma of the Uterine Cervix to Paclitaxel, Carboplatin, and Bevacizumab Combination Therapy
Carboplatin and nab-paclitaxel chemotherapy with or without atezolizumab as front-line management for treatment-naïve metastatic nonsquamous non-small cell lung cancer with PD-L1 staining: a retrospective study
Adjuvant Atezolizumab-Bevacizumab after Resection or Ablation for Hepatocellular Carcinoma
Bayesian Analysis Supports Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
Paclitaxel und Paclitaxel-Carboplatin beim fortgeschrittenen nichtkleinzelligen Bronchialkarzinom : Auswertung klinischer Phase-II-Studien
To assess the role of addition of bevacizumab therapy to carboplatin and paclitaxel as frontline treatment of epithelial ovarian cancer
A randomized, controlled trial evaluating the efficacy and safety of BTH1677 in combination with bevacizumab, carboplatin, and paclitaxel in first-line treatment of advanced non-small cell lung cancer
Atezolizumab (NSCLC; Kombination mit Bevacizumab, Carboplatin und Paclitaxel) : Nutzenbewertung gemäß § 35a SGB V
Atezolizumab (NSCLC, Kombination mit nab-Paclitaxel und Carboplatin) : Nutzenbewertung gemäß § 35a SGB V
Atezolizumab (NSCLC, Kombination mit nab-Paclitaxel und Carboplatin) : Nutzenbewertung gemäß § 35a SGB V
Phase II study of carboplatin/nab-paclitaxel/atezolizumab combination therapy for advanced nonsquamous non–small cell lung cancer patients with impaired renal function: RESTART trial
[18F]FDG PET/CT-based response assessment of stage IV non-small cell lung cancer treated with paclitaxel-carboplatin-bevacizumab with or without nitroglycerin patches
Complete Response of Recurrent Small Cell Carcinoma of the Uterine Cervix to Paclitaxel, Carboplatin, and Bevacizumab Combination Therapy
Carboplatin and nab-paclitaxel chemotherapy with or without atezolizumab as front-line management for treatment-naïve metastatic nonsquamous non-small cell lung cancer with PD-L1 staining: a retrospective study
Adjuvant Atezolizumab-Bevacizumab after Resection or Ablation for Hepatocellular Carcinoma
Bayesian Analysis Supports Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
Paclitaxel und Paclitaxel-Carboplatin beim fortgeschrittenen nichtkleinzelligen Bronchialkarzinom : Auswertung klinischer Phase-II-Studien
To assess the role of addition of bevacizumab therapy to carboplatin and paclitaxel as frontline treatment of epithelial ovarian cancer
A randomized, controlled trial evaluating the efficacy and safety of BTH1677 in combination with bevacizumab, carboplatin, and paclitaxel in first-line treatment of advanced non-small cell lung cancer
Atezolizumab (NSCLC; Kombination mit Bevacizumab, Carboplatin und Paclitaxel) : Nutzenbewertung gemäß § 35a SGB V
Atezolizumab (NSCLC, Kombination mit nab-Paclitaxel und Carboplatin) : Nutzenbewertung gemäß § 35a SGB V
Atezolizumab (NSCLC, Kombination mit nab-Paclitaxel und Carboplatin) : Nutzenbewertung gemäß § 35a SGB V
Phase II study of carboplatin/nab-paclitaxel/atezolizumab combination therapy for advanced nonsquamous non–small cell lung cancer patients with impaired renal function: RESTART trial
[18F]FDG PET/CT-based response assessment of stage IV non-small cell lung cancer treated with paclitaxel-carboplatin-bevacizumab with or without nitroglycerin patches
Complete Response of Recurrent Small Cell Carcinoma of the Uterine Cervix to Paclitaxel, Carboplatin, and Bevacizumab Combination Therapy
Carboplatin and nab-paclitaxel chemotherapy with or without atezolizumab as front-line management for treatment-naïve metastatic nonsquamous non-small cell lung cancer with PD-L1 staining: a retrospective study
Adjuvant Atezolizumab-Bevacizumab after Resection or Ablation for Hepatocellular Carcinoma
Bayesian Analysis Supports Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
Paclitaxel und Paclitaxel-Carboplatin beim fortgeschrittenen nichtkleinzelligen Bronchialkarzinom : Auswertung klinischer Phase-II-Studien
To assess the role of addition of bevacizumab therapy to carboplatin and paclitaxel as frontline treatment of epithelial ovarian cancer